Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma

Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a surface marker that is highly expressed on normal and...

Descripción completa

Detalles Bibliográficos
Autores principales: Friend, Reed, Bhutani, Manisha, Voorhees, Peter M, Usmani, Saad Z
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367738/
https://www.ncbi.nlm.nih.gov/pubmed/28356715
http://dx.doi.org/10.2147/DDDT.S98053
_version_ 1782517822129176576
author Friend, Reed
Bhutani, Manisha
Voorhees, Peter M
Usmani, Saad Z
author_facet Friend, Reed
Bhutani, Manisha
Voorhees, Peter M
Usmani, Saad Z
author_sort Friend, Reed
collection PubMed
description Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a surface marker that is highly expressed on normal and malignant plasma cells. This review summarizes the preclinical and clinical data that led to the approval of elotuzumab, along with a discussion on the ongoing and future clinical investigations.
format Online
Article
Text
id pubmed-5367738
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-53677382017-03-29 Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma Friend, Reed Bhutani, Manisha Voorhees, Peter M Usmani, Saad Z Drug Des Devel Ther Review Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a surface marker that is highly expressed on normal and malignant plasma cells. This review summarizes the preclinical and clinical data that led to the approval of elotuzumab, along with a discussion on the ongoing and future clinical investigations. Dove Medical Press 2017-03-20 /pmc/articles/PMC5367738/ /pubmed/28356715 http://dx.doi.org/10.2147/DDDT.S98053 Text en © 2017 Friend et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Friend, Reed
Bhutani, Manisha
Voorhees, Peter M
Usmani, Saad Z
Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
title Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
title_full Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
title_fullStr Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
title_full_unstemmed Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
title_short Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
title_sort clinical potential of slamf7 antibodies – focus on elotuzumab in multiple myeloma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367738/
https://www.ncbi.nlm.nih.gov/pubmed/28356715
http://dx.doi.org/10.2147/DDDT.S98053
work_keys_str_mv AT friendreed clinicalpotentialofslamf7antibodiesfocusonelotuzumabinmultiplemyeloma
AT bhutanimanisha clinicalpotentialofslamf7antibodiesfocusonelotuzumabinmultiplemyeloma
AT voorheespeterm clinicalpotentialofslamf7antibodiesfocusonelotuzumabinmultiplemyeloma
AT usmanisaadz clinicalpotentialofslamf7antibodiesfocusonelotuzumabinmultiplemyeloma